NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Quantum BioPharma's Private Placement of Class A Multiple Voting Shares
TL;DR
Quantum BioPharma's private placement gives controlling shareholders 75% voting power, securing strategic control for advancing neurodegenerative and metabolic disorder treatments.
Quantum BioPharma will issue 30 Class A shares at $25 each in a non-brokered private placement, raising $750 for general working capital purposes.
This funding supports Quantum BioPharma's development of treatments for multiple sclerosis and alcohol misuse disorders, potentially improving patient outcomes worldwide.
Quantum BioPharma retains 20% ownership in Unbuzzd Wellness and receives royalties up to $250 million from their consumer health product sales.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share for gross proceeds of up to $750.
The offering is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz.
Upon completion, the voting rights attached to the Class A shares will increase to 75.27%, restoring them to nearly their original level when the Company went public in 2018.
The proceeds will be used for general working capital purposes.
The offering was approved by shareholders on September 26, 2025.
Quantum BioPharma focuses on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, with drug candidates in different stages of development.
Through its subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma is developing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. and receives royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity.
The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM
InvestorWire is a specialized communications platform that provides advanced wire-grade press release syndication and is part of the Dynamic Brand Portfolio @ IBN that distributed this content.
Curated from InvestorBrandNetwork (IBN)
